Joshua R. Disbrow bought $100k of AYTU
Chief Executive Officer at AYTU BIOPHARMA, INC. 66,666 shares at an average of $1.50, traded Jun 9, 2025, filed Jun 10, 2025.
Score components
- +25RoleCEO
- +10Trade size$100k at market
- +10Relative to holdingsHoldings up 77%
- +4Price context26% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +13.4%, 3m +15.3%, 6m +11.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-25-019956, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 9, 2025 | POpen-market purchase Common Stock | +66,666 | $1.50 | $100k | 153,257 | Jun 10, 2025 |
Related signals
Other insiders at AYTU BIOPHARMA, INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 37Weak | AYTU BIOPHARMA, INC | Jarrett Disbrow Chief Business Officer | $25k 16,666 shares | +130% | |
| 31Weak | AYTUbuy AYTU BIOPHARMA, INC | Joshua R. Disbrow Chief Executive Officer | $20k 15,000 shares | +21% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.